

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Neurological Disorders and Stroke, Division of Extramural Activities; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting:

Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel (Telephone Conference call).

Date: April 23, 1997.

Time: 1:00 p.m.

Place: National Institutes of Health, 7550 Wisconsin Avenue, Room 9C10, Bethesda, MD 20892.

Contact Person: Dr. Howard Weinstein, Scientific Review Administrator, National Institutes of Health, 7550 Wisconsin Avenue, Room 9C10, Bethesda, MD 20892, (301) 496-9223.

Purpose/Agenda: To review and evaluate an SBIR Phase II Contract Proposal.

The meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance Program No. 93.853, Clinical Research Related to Neurological Disorders; No. 93.854, Biological Basis Research in the Neurosciences)

Dated: April 7, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97-9299 Filed 4-9-97; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of Research on Women's Health; Notice of Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the meeting of the Advisory Committee on Research on Women's Health (ACRWH) to be held May 5-6, 1997, National Institutes of Health, 9000 Rockville Pike, Building

31, C Wing, Conference Room 10, Bethesda, Maryland 20892.

The entire meeting will be open to the public from 8:30 a.m., May 5, to adjournment on May 6. The purpose of the meeting will be for the Committee to provide advice to the Office of Research on Women's Health (ORWH) on its research agenda and to provide recommendations regarding ORWH activities.

The agenda will include an update on ORWH activities and programs to meet the mandates of the Office and discussion of scientific issues. The Committee will hear scientific presentations from several NIH institute directors, as well as an update from the Deputy Assistant Secretary for Health (Women's Health). The Committee will also discuss activities related to its regional meetings to update the research agenda on women's health. Attendance by the public will be limited to space available.

Anne R. Bavier, M.N., F.A.A.N., Executive Secretary, ACRWH, and Deputy Director, Office of Research on Women's Health, OD, NIH, Building 1, Rm. 201, Bethesda, Maryland 20892, 301/402-1770, 301/402-1798 (Fax), will furnish the meeting agenda, roster of Committee members, and substantive program information upon request.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Bavier in advance of the meeting.

Dated: April 7, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97-9300 Filed 4-9-97; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service

National Institutes of Health

Office of Research on Women's Health; Notice of Meeting—"Beyond Hunt Valley: Research on Women's Health for the 21st Century"

Notice is hereby given that the Office of Research on Women's Health, Office of the Director, National Institutes of Health, will convene a meeting on June 11, 12, and 13, 1997, at the Sheraton New Orleans Hotel, New Orleans, Louisiana. The purpose of the meeting is to update the current biomedical and behavioral research agenda for women's health, as presented in the Report of the

National Institutes of Health: Opportunities for Research on Women's Health, a publication based on a conference held in Hunt Valley, Maryland, September 1991.

The NIH/FAES is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical educations for physicians.

The NIH/FAES designates this educational activity for a maximum of 10 hours in category 1 credit towards the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

The first day, June 11, will be devoted to receiving public testimony from 1:00 p.m. to 5:00 p.m. from individuals and individuals representing organizations interested in biomedical and behavioral research on women's health issues. On June 12 and 13, concurrent working groups will discuss women's health research, with particular reference to gender differences and emerging scientific issues. The schedule for June 22 is 8:30 a.m. to 5:30 p.m. and on June 23 the meeting will end approximately at 3:00 p.m. All sessions of the meeting are open to the public.

The purpose of this conference is to examine the physiological and psychosocial differences which exist between women and men and emerging scientific issues such as the environmental impact on women's health. In addition, strategies based upon the research which can result in an improved health status for all women will be developed.

Experts in fields of basic and clinical science, practitioners interested in women's health, representatives of scientific, professional and women's health organizations, and women's health advocates will be asked to assess the current status of research in women's health, in these, and other areas, identify gaps in existing knowledge, and recommend scientific approaches and strategies to take advantage of promising opportunities for research on women's health.

Opening sessions will be devoted to identifying those factors which may influence health status, including physiological and psychological differences between women and men, and to addressing the emerging issues from basic science to clinical studies through application to all women regardless of race, ethnicity, or age with special focus on the effects of environmental hazards and toxins across the life span.

The Office of Research on Women's Health invites individuals and individuals representing organizations with an interest in research areas related to women's health to provide written and oral testimony on the state of knowledge and continuing or emerging gaps in knowledge about women's health across the life span, sex/gender differences and the impact on women's health, new priorities for research on women's health, the environmental, genetic, hormonal, non-hormonal, and other factors that impact women's health, and career issues for women scientists and how to overcome the barriers. Due to time constraints, only one representative from each organization may present oral testimony, with presentations limited to 10 minutes. A letter of intent to present such testimony should be sent by interested individuals and organizations to Ms. Maxine Smith, Houston Associates, 1010 Wayne Avenue, Suite 1200, Silver Spring, MD 20910. Presenters should send three (3) written copies of their testimony, including a brief description of their organization, to the above address no later than May 20, 1997. The date of receipt of the letter will establish the order of presentations at the June meeting.

Individuals and organizations wishing to provide written statements only may send three (3) copies of their statements to the above address by May 20, 1997. All written testimony will be made available to the conferees prior to the June 11 meeting day. Comments and questions related to the June meeting should be addressed to Ms. Smith.

This meeting is the second of three regional public hearings and scientific workshops of similar design to be convened by the Office of Research on Women's Health. At the conclusion of this series of meetings, the Office of Research on Women's Health will convene a national meeting to address the deliberations and recommendations from the regional public hearings and scientific workshops for the purpose of developing a report for priorities for research on women's health for the 21st century.

Dated: April 3, 1997.

Ruth L. Kirschstein,

Deputy Director, NIH.

[FR Doc. 97-9301 Filed 4-9-97; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Method of Identifying Persons Susceptible to Autoimmune Neuropsychiatric Disorders

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license to practice its interest in the invention embodied in U.S. Patent Application Serial No. 08/473,033, filed June 6, 1995, entitled, "Method of Identifying Persons Susceptible to Autoimmune Neuropsychiatric Disorders," and subsequent filings, to Callisto Pharmaceuticals, Inc., having a place of business in New York, New York. The United States is a joint assignee of the patent rights in these inventions.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. the prospective exclusive license may be granted unless, within 90 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The field of use would be diagnosing persons with, or at risk of developing, certain neuropsychiatric disorders as described in the patent application.

SUPPLEMENTARY INFORMATION: Obsessive compulsive disorder is a severe debilitating condition that can interfere dramatically with daily activities. Obsessive thoughts can include worries about either personal or family safety, past actions, or fears of contamination. Currently there is no known biologic or genetic marker diagnostic for this disorder. However, there is evidence that certain autoimmune diseases have accompanying psychological symptoms including obsessive compulsive behavior, attention deficit hyperactivity disorder, emotional lability, and irritability. The patent application relates to the discovery that in patients at risk for developing neuropsychiatric disorders due to autoimmune disease there is a dramatic increase in the number of B lymphocytes expressing an alloantigen. Detection of the antigen has

been shown to be predictive for obsessive compulsive behavior. In addition, individuals at genetic risk for these neuropsychiatric disorders can also be identified.

ADDRESSES: Requests for a copy of the patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to: Leopold J. Luberecki, Jr., J.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Box 13, Rockville, MD 20852-3804; Telephone: (301) 496-7735, ext. 223; Facsimile: (301) 402-0220. Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before July 9, 1997 will be considered.

Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: March 31, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 97-9237 Filed 4-9-97; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[OR-118-6332-00; GP7-0136]

Closure of All Segments of the London Peak Overlook Trail to Off-Highway and Mechanized Vehicle Use

AGENCY: Bureau of Land Management, Medford District Office.

ACTION: Emergency closure of public land trail in Josephine County, Oregon.

SUMMARY: Notice is hereby given that effective immediately, all segments of the London Peak Overlook Trail under Bureau of Land Management control are closed to all uses other than foot traffic or wheelchairs. The closure is made under the authority of 43 CFR 8341.2. The closure will remain in effect until such time that changes in resource management warrant modifications.

The public lands affected by this emergency closure are specifically identified as follows:

London Peak Overlook Trail on BLM lands in T.33 S., R. 6 W., Section 21, Willamette